|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Attenuated fibrinolysis and accelerated atherogenesis in type 2 diabetic patients显示文摘 | Schneider DJ Nordt TK Sobel BE | | 0，，： | 2 |
| 2 | A review of metabolic and cardiovascular effects of oral antidiabetic agents:beyond glucose-level lowering显示文摘 | Plutzky J Sobel BE | 1999 | J Cardiovasc Risk1999，6，： | 1 |
| 3 | Medical educationg, evidence based medicine, and the disqualification of physician scientists显示文摘 | SOBEL BE LEVINE MA | 2001 | ExpBiollvled2001，226，3： | 1 |
| 4 | Attenuation of thrombolysis by release of plasminogen activator inhibitor type 1 from platelets显示文摘 | Torr-Brown SR Sobel BE | 1993 | Thromb Res1993，72，： | 1 |
| 5 | Effect of fatty acid chain length and thioesterification on the augmentation of expression of plasminogen activator inhibitor-1 显示文摘 | CHEN Y SOBEL BE SCHEIDER DJ | 2002 | Nutr Metab Cardiovasc Dis2002，12，6： | 1 |
| 6 | Intramural Plasminogen Activa- tor Inhibitor Type-1 and Coronary Atherosclerosis 显示文摘 | Sobel BE Taatjes DJ Schneider DJ | 2003 | Arterioscler Thromb Vase Biol2003，23，11： | 1 |
| 7 | Determination of coronary vascular disease in patients withtype 2 diabetic mellitus and their therapeutic implication显示文摘 | Schneider DH Sobel BE | 1997 | ClinCardiol1997，20，： | 1 |
| 8 | Comparison ofplasminogen activator inhibitor -1, tissue type plasminogenactivator antigen, fibrinogen, and D-dimer levels in variousage decades in patients with type 2 diabetes mellitus and stablecoronary artery disease (from the BARI 2D trial) 显示文摘 | Mcbane RN Hardison RM Sobel BE | 2010 | Am JCardiol’2010，105，1： | 1 |
| 9 | Increasedplasminogen activator inhibitor type 1 in coronary artery atherecto-my specimens from type 2 diabetic compared with nondiabetic pa-tients :a potential factor predisposing to thrombosis and its persist-ence 显示文摘 | Sobel BE Woodcock-Mitchell J Schneider DJ | 1998 | Circulation1998，97，22： | 1 |
| 10 | Ultrasonic tissue characterization:prospects for clinical cardiology 显示文摘 | Wickline SA Sobel BE | 1989 | J Am Coil Cardiol1989，14，： | 1 |
| 11 | Enhancement by growth factors of cardiacmyocyte differentiation from embryonic stem cells:a promising foundation for cardiac regeneration显示文摘 | Singla DK Sobel BE | 2005 | Biochem Biophys Res Commun2005，335，3： | 1 |
| 12 | Medical education,evidence-based medicine,and the disqualification of physieian-seientists显示文摘 | Sobel BE Levine MA | 2001 | Exp Bid Med2001，226，： | 1 |
| 13 | Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA)显示文摘 | Eisenberg PR Miletich JP Sobel BE | 1988 | Thromb Research1988，50，： | 1 |
| 14 | Factors influencing infarct size following experimental coronary artery occlusion显示文摘 | Maroko PR Kjekshus J Sobel BE | 1991 | Circulation1991，43，1： | 1 |
| 15 | Insulin resistance and thrombosis:a cardiologist's view显示文摘 | | 1999 | Am J Cardiol1999，84，： | 1 |
| 16 | Troglitazone improve defect in insulin action,insulin secretion,ovarian steroielgengsis and fibrinolysis in women with polycystic ovary syndrome显示文摘 | Ehrmann DA Schnoider DJ Sobel BE | 1997 | J Clin Endocrinol Metab1997，82，7： | 1 |
| 17 | Troglitazone improves defects in insulin action,insulin secretion,ovarian steroidogenesis,and fibrinolysis in women with polycystic ovary syndrome显示文摘 | Ehrmann DA Schneider DJ Sobel BE | 1997 | J Clin Endocrinol Metab1997，82，7： | 1 |
| 18 | Troglitazone improve defects in isulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome 显示文摘 | Ehrmann DA Schneider DJ Sobel BE | 1997 | J Clin Endocriol Motabolism1997，82，7： | 1 |
| 19 | Aging and high concentrations of glucose po- tentiate injury to mitochondrial DNA 显示文摘 | FUKAGAWA NK LI M HANG P RUSSELL JC SOBEL BE ABSHER PM | 1999 | Free Radic Biol Med1999，27，1112： | 1 |
| 20 | Effects of glycemie control and other determinants on vascular disease in type 2diabetes显示文摘 | Sobel BE | 2002 | Am J Meal2002，113，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员